Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial

Melanie Schmidt, Nadja Pfetzer, Micheal Schwab, Ingrid Strauss, Ulrike Kämmerer, Melanie Schmidt, Nadja Pfetzer, Micheal Schwab, Ingrid Strauss, Ulrike Kämmerer

Abstract

Background: Tumor patients exhibit an increased peripheral demand of fatty acids and protein. Contrarily, tumors utilize glucose as their main source of energy supply. Thus, a diet supplying the cancer patient with sufficient fat and protein for his demands while restricting the carbohydrates (CHO) tumors thrive on, could be a helpful strategy in improving the patients' situation. A ketogenic diet (KD) fulfills these requirements. Therefore, we performed a pilot study to investigate the feasibility of a KD and its influence on the quality of life of patients with advanced metastatic tumors.

Methods: Sixteen patients with advanced metastatic tumors and no conventional therapeutic options participated in the study. The patients were instructed to follow a KD (less than 70 g CHO per day) with normal groceries and were provided with a supply of food additives to mix a protein/fat shake to simplify the 3-month intervention period. Quality of life [assessed by EORTC QLQ-C30 (version 2)], serum and general health parameters were determined at baseline, after every two weeks of follow-up, or after drop out. The effect of dietary change on metabolism was monitored daily by measuring urinary ketone bodies.

Results: One patient did not tolerate the diet and dropped out within 3 days. Among those who tolerated the diet, two patients died early, one stopped after 2 weeks due to personal reasons, one felt unable to stick to the diet after 4 weeks, one stopped after 6 and two stopped after 7 and 8 weeks due to progress of the disease, one had to discontinue after 6 weeks to resume chemotherapy and five completed the 3 month intervention period. These five and the one who resumed chemotherapy after 6 weeks report an improved emotional functioning and less insomnia, while several other parameters of quality of life remained stable or worsened, reflecting their very advanced disease. Except for temporary constipation and fatigue, we found no severe adverse side effects, especially no changes in cholesterol or blood lipids.

Conclusions: These pilot data suggest that a KD is suitable for even advanced cancer patients. It has no severe side effects and might improve aspects of quality of life and blood parameters in some patients with advanced metastatic tumors.

Figures

Figure 1
Figure 1
Study design. The course of the study plan, including the intervals of data acquisition is shown in this diagram.
Figure 2
Figure 2
Trial profile flow diagram. A trial profile corresponding to the CONSORT criteria is shown indicating the course of the pilot study
Figure 3
Figure 3
Course of urinary ketones. Typical examples of urinary ketone data are shown for three patients reaching ketonuria (A) and three who failed to reach ketonuria on the majority of days (B). The first 50 days of the intervention period are shown
Figure 4
Figure 4
Quality of life. Summary of the EORTC QLQ-C30 (version 2) questionnaires. A): Global health status and functional score remained relatively stable during the time evaluated while the global symptom score increased slightly. B) Subdivision of functional scores shows a slight decrease in physical and role functioning, an increase in emotional functioning and stable cognitive as well as social functioning. C) Concerning digestive functions, the symptoms score showed an increase in appetite loss, constipation or diarrhoea in the first four weeks of the diet. Symptoms then remain stable and signs of diarrhoea diminish. D) The other symptoms were an increase in fatigue and pain corresponding to the very advanced tumor situation. However, insomnia clearly decreased with ongoing dieting. Graphs are given as means for the seven evaluable patients.
Figure 5
Figure 5
Blood parameters. The courses of the blood parameters for the 11 evaluable patients at start of study and after at least 6 weeks of dieting are shown. While the blood glucose (A), creatinine (B), albumin (C) and triglycerides (D) did not change much, leukocyte count increased significantly (E) and cholesterol (F), LDL (G) and LDL/HDL (H) decreased significantly. The patients', ALT dropped significantly (I) while blood urea increased, albeit remaining in normal range (J). Dotted lines: upper and lower level of normal range.

References

    1. Warburg O, Minami S. Versuche am überlebenden Carzinom-Gewebe. Klin Wochenschr. 1923;2:776–777. doi: 10.1007/BF01712130.
    1. Warburg O. On the origin of cancer cells. Science. 1956;123:309–314. doi: 10.1126/science.123.3191.309.
    1. Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A, Saavedra E. Energy metabolism in tumor cells. FEBS J. 2007;274:1393–1418. doi: 10.1111/j.1742-4658.2007.05686.x.
    1. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev. 2008;18:54–61. doi: 10.1016/j.gde.2008.02.003.
    1. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25:4633–4646. doi: 10.1038/sj.onc.1209597.
    1. Chen Z, Lu W, Garcia-Prieto C, Huang P. The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr. 2001;39:267–274.
    1. Rodríguez-Enríquez S, Marín-Hernández A, Gallardo-Pérez JC, Carreño-Fuentes L, Moreno-Sánchez R. Targeting of cancer energy metabolism. Mol Nutr Food Res. 2009;53:29–48. doi: 10.1002/mnfr.200700470.
    1. Freund E. Zur Diagnose des Carzinoms. Vorläufige Mittheilung. Wien Med Bl. 1885;8:267.
    1. Händel M, Tadenuma K. Über die Beziehung des Geschwulstwachstums zur Ernährung und zum Stoffwechsel. II. Mitteilung. Versuche zur Frage der Bedeutung der Kohlenhydrate für das Wachstum des Rattencarzinoms. Z Krebsforsch (J Cancer Res and Clin Oncol) 1924;21:288–293.
    1. Marks PA, Bishop JS. The glucose metabolism of patients with malignant disease and of normal subjects as studied by means of an intravenous glucose tolerance test. J Clin Invest. 1957;36:254–264. doi: 10.1172/JCI103419.
    1. Zuijdgeest-van Leeuwen SD, van den Berg JW, Wattimena JL, van der Gaast A, Swart GR, Wilson JH, Dagnelie PC. Lipolysis and lipid oxidation in weight-losing cancer patients and healthy subjects. Metabolism. 2000;49:931–6. doi: 10.1053/meta.2000.6740.
    1. Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, Elstrom RL, Thompson CB. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene. 2005;24:4165–4173. doi: 10.1038/sj.onc.1208622.
    1. Zhou W, Mukherjee P, Kiebish MA, Markis WT, Mantis JG, Seyfried TN. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab (Lond) 2007;4:5. doi: 10.1186/1743-7075-4-5.
    1. Fine EJ, Miller A, Quadros EV, Sequeira JM, Feinman RD. Acetoacetate reduces growth and ATP concentration in cancer cell lines which over-express uncoupling protein 2. Cancer Cell Int. 2009;29:14.
    1. Skinner R, Trujillo A, Ma X, Beierle EA. Ketone bodies inhibit the viability of human neuroblastoma cells. J Pediatr Surg. 2009;44:212–6. doi: 10.1016/j.jpedsurg.2008.10.042.
    1. Holm E, Hagmüller E, Staedt U, Schlickeiser G, Günther HJ, Leweling H, Tokus M, Kollmar HB. Substrate balances across colonic carcinomas in humans. Cancer Res. 1995;55:1373–8.
    1. Lieb CW. The Effects on Human Beings of a Twelve Months' Exclusive Meat Diet. JAMA. 1929;93:20–22.
    1. Wilder RM. The effect of ketonemia on the course of epilepsy. Mayo Clin Bulletin. 1921;2:307–308.
    1. Kosoff EH. More fat and fewer seizure: diatary therapies for epilepsy. Lancet Neurol. 2004;3:415–420. doi: 10.1016/S1474-4422(04)00807-5.
    1. Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, Whitney A, Cross JH. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008;7:500–506. doi: 10.1016/S1474-4422(08)70092-9.
    1. Wiznitzer M. From observations to trials: the ketogenic diet and epilepsy. Lancet Neurol. 2008;7:471–472. doi: 10.1016/S1474-4422(08)70093-0.
    1. Atkins RC. Dr. Atkins' diet revolution. The high calorie way to stay thin forever. D. McKay Co, New York; 1972.
    1. Kirby RK. 2005.
    1. Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, Williams T, Williams M, Gracely EJ, Stern L. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med. 2003;348:2074–2081. doi: 10.1056/NEJMoa022637.
    1. Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, Golan R, Fraser D, Bolotin A, Vardi H, Tangi-Rozental O, Zuk-Ramot R, Sarusi B, Brickner D, Schwartz Z, Sheiner E, Marko R, Katorza E, Thiery J, Fiedler GM, Blüher M, Stumvoll M, Stampfer MJ. Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008;359:229–241. doi: 10.1056/NEJMoa0708681.
    1. Nebeling LC, Miraldi F, Shurin SB, Lerner E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr. 1995;14:202–208.
    1. Freund E. Über den Einfluß verschiedener Ernährung auf Tumorempfänglichkeit und Tumorwachstum bei Mäusen. Z Krebsforsch (J Cancer Res and Clin Oncol) 1932;37:354–361.
    1. Caspari W. Über den Einfluß der Kost auf das Wachstum von Impfgeschwüren. VI. Mitteilung. Über den Einfluß des Palmitins auf das Geschwulstwachstum. Z Krebsforsch (J Cancer Res and Clin Oncol) 1933;38:355–360.
    1. Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, Mukherjee P, Seyfried TN. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. Nutr Metab (Lond) 2010;22:33.
    1. Magee BA, Potezny N, Rofe AM, Conyers RA. The inhibition of malignant cell growth by ketone bodies. Aust J Exp Biol Med Sci. 1979;57:529–539. doi: 10.1038/icb.1979.54.
    1. Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, Cohen P, Hwang D, Peterson B, Fields T, Pizzo SV, Isaacs WB. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate. 2008;68:11–19. doi: 10.1002/pros.20683.
    1. Hardman WE. Dietary canola oil suppressed growth of implanted MDA-MB 231 human breast tumors in nude mice. Nutr Cancer. 2007;57:177–183. doi: 10.1080/01635580701277445.
    1. Otto C, Kaemmerer U, Illert B, Muehling B, Pfetzer N, Wittig R, Voelker HU, Thiede A, Coy JF. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer. 2008;30:122.
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osboa D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376. doi: 10.1093/jnci/85.5.365.
    1. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2:187–93.
    1. Breitkreutz R, Tesdal K, Jentschura D, Haas O, Leweling H, Holm E. Effects of a high-fat diet on body composition in cancer patients receiving chemotherapy: a randomized controlled study. Wien Klin Wochenschr. 2005;117:685–692. doi: 10.1007/s00508-005-0455-3.
    1. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655. doi: 10.1097/00000421-198212000-00014.
    1. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, EORTC Quality of Life Group. 2001.
    1. Holm S. A simple sequentially rejective multiple test procedure. Scand J Statistics. 1979;6:65–70.
    1. Mosek A, Natour H, Neufeld MY, Shiff Y, Vaisman N. Ketogenic diet treatment in adults with refractory epilepsy: A prospective pilot study. Seizure. 2007;18:30–33.
    1. Jones LW, Demark-Wahnefried W. Diet, exercise, and complementary therapies after primary treatment for cancer. Lancet Oncol. 2006;7:1017–26. doi: 10.1016/S1470-2045(06)70976-7.
    1. Ernst E. The role of complementary and alternative medicine in cancer. Lancet Oncol. 2000;1:176–80. doi: 10.1016/S1470-2045(00)00031-0.
    1. Brown AJ. Low-carb diets, fasting and euphoria: Is there a link between ketosis and gamma-hydroxybutyrate (GHB)? Med Hypotheses. 2007;68:268–271. doi: 10.1016/j.mehy.2006.07.043.
    1. Nuttall FQ, Ngo A, Gannon MC. Regulation of hepatic glucose production and the role of gluconeogenesis in humans: is the rate of gluconeogenesis constant? Diabetes Metab Res Rev. 2008;24:438–458. doi: 10.1002/dmrr.863.
    1. Holroyde CP, Gabuzda TG, Putnam RC, Paul P, Reichard GA. Altered glucose metabolism in metastatic carcinoma. Cancer Res. 1975;35:3710–3714.
    1. Beliveau R, Gingras D. Krebszellen mögen keine Himberen (Les aliments contre le cancer) München: Kösel-Verlag; 2008.
    1. Turan S, Omar A, Bereket A. Comparison of capillary blood ketone measurement by electrochemical method and urinary ketone in treatment of diabetic ketosis and ketoacidosis in children. Acta Diabeto. 2008;45:83–5. doi: 10.1007/s00592-008-0026-y.
    1. Adam-Perrot A, Clifton P, Brouns F. Low-carbohydrate diets: nutritional and physiological aspects. Obes Rev. 2006;7:49–58. doi: 10.1111/j.1467-789X.2006.00222.x.
    1. Gardner CD, Kiazand A, Alhassan S, Kim S, Stafford RS, Balise RR, Kraemer HC, King AC. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA. 2007;297:969–977. doi: 10.1001/jama.297.9.969.
    1. Berquin IM, Edwards IJ, Chen YQ. Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett. 2008;269:363–377. doi: 10.1016/j.canlet.2008.03.044.
    1. Colomer R, Moreno-Nogueira JM, García-Luna PP, García-Peris P, García-de-Lorenzo A, Zarazaga A, Quecedo L, del Llano J, Usán L, Casimiro C. N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Br J Nutr. 2007;97:823–831. doi: 10.1017/S000711450765795X.
    1. Hardman WE. (n-3) fatty acids and cancer therapy. J Nutr. 2004;134(12 Suppl):3427S–3430S.
    1. Gutt CN, Brinkmann L, Mehrabi A, Fonouni H, Müller-Stich BP, Vetter G, Stein JM, Schemmer P, Büchler MW. Dietary omega-3-polyunsaturated fatty acids prevent the development of metastases of colon carcinoma in rat liver. Eur J Nutr. 2007;46:279–285. doi: 10.1007/s00394-007-0662-y.
    1. Fearon KC, Borland W, Preston T, Tisdale MJ, Shenkin A, Calman KC. Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism. Am J Clin Nutr. 1988;47:42–48.
    1. Fine EJ, Segal-Isaacson CJ, Feinman R, Sparano J. Carbohydrate restriction in patients with advanced cancer: a protocol to assess safety and feasibility with an accompanying hypothesis. Commun Oncol. 2008;5:22–26.
    1. Clinical trials homepage. registration numbers: , , , .

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다